La Jolla Pharmaceutical Co. buy melinda
Start price
25.10.18
/
50%
?16.08
Target price
30.10.19
€31.57
Performance (%)
0.00%
End price
30.10.19
-
Summary
This prediction ended on 30.10.19 with a price of -. melinda's BUY prediction for La Jolla Pharmaceutical Co. closed unchanged from the start price. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| La Jolla Pharmaceutical Co. | - | - | - | - |
| iShares Core DAX® | -0.130% | 1.601% | 13.900% | 16.793% |
| iShares Nasdaq 100 | -5.156% | -2.343% | 30.120% | 47.391% |
| iShares Nikkei 225® | -3.402% | 2.990% | 12.946% | 9.565% |
| iShares S&P 500 | -1.733% | 0.290% | 28.669% | 44.958% |
Comments by melinda for this prediction
In the thread La Jolla Pharmaceutical Co. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 24/10 Publication de résultats
Operates as a biopharmaceutical company
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.
Its products includes LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb.
LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone.
The LJPC-30Sa and LJPC-30Sb are the next generation gentamicin derivatives, which is an antibiotic for kidney toxicity.
The firm also provides GIAPREZA, angiotensin II which increases blood pressure in adults with septic and other distributive shock.
The company was founded in 1989 and is headquartered in San Diego, CA.
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.
Its products includes LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb.
LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone.
The LJPC-30Sa and LJPC-30Sb are the next generation gentamicin derivatives, which is an antibiotic for kidney toxicity.
The firm also provides GIAPREZA, angiotensin II which increases blood pressure in adults with septic and other distributive shock.
The company was founded in 1989 and is headquartered in San Diego, CA.
Nombre d'employés : 309 personnes.
Es gibt keinen Handelsplatz
Stopped prediction by melinda for La Jolla Pharmaceutical Co.
La Jolla Pharmaceutical Co.
Start price
Target price
Perf. (%)
?34.47
04.02.18
04.02.18
€39.60
06.08.18
06.08.18
-10.97%
06.08.18
06.08.18
La Jolla Pharmaceutical Co.
Start price
Target price
Perf. (%)
?27.15
22.12.17
22.12.17
€72.16
29.12.17
29.12.17
7.84%
29.12.17
29.12.17
La Jolla Pharmaceutical Co.
Start price
Target price
Perf. (%)
?29.10
29.08.17
29.08.17
€72.16
29.08.17
29.08.17
7.19%
29.08.17
29.08.17
La Jolla Pharmaceutical Co.
Start price
Target price
Perf. (%)
?22.65
12.04.17
12.04.17
€28.86
21.04.17
21.04.17
11.91%
21.04.17
21.04.17